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initial lumpectomy is the preferred option rather than 
delayed administration by reopening the wound. We 
therefore estimated the number of cancer foci in quadrants 
other than the original tumour and compared the incidence 
of recurrence in such quadrants as per treatment received 
(TARGIT vs. EBRT). 
Results: 793 patients in the prepathology stratum 
randomized to TARGIT had only TARGIT as their radiotherapy 
and had. 2098 women years of follow up. The 5 year local 
recurrence rate in those who received TARGIT alone was 2.7% 
(95% CI 1.35.5), which was not different from the whole 
prepathology cohort randomized to TARGIT: 2.1% (1.14.2). In 
these 793 patients, one would expect 63% (i.e., 500) of 
patients to have additional foci of cancer in their breasts and 
80% of these (i.e., 400) should be in quadrants other than the 
index quadrant. In reality, after 2098 women years of follow 
up, 7 patients had recurrence in the scar, 6 had new 
contralateral cancers and 2 had cancers growing in other 
quadrants implying that the remaining 398 foci had remained 
dormant. Amongst 935 patients who received whole breast 
radiotherapy the same number of cancers (n=2) grew in other 
quadrants and there were 5 new contralateral cancers. Of 
note, 94.4% of cases in the TARGIT A trial did not have a 
preoperative MRI, so patients who may have had multicentric 
foci detectable by MRI would have not been excluded from 
the trial. 
Conclusions: Cancer foci in breast that are away from the 
site of the primary tumour remain dormant and behave no 
differently from those in the contralateral breast. They also 
appear to be unaffected by whole breast radiotherapy or are 
treated sufficiently by systemic therapies. This analysis from 
the randomized TARGIT A trial provides further proof 
supporting partial breast irradiation. 
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Purpose/Objective: A joint analysis of clinical and technical 
data from 34 centres within the International Society of 
Intraoperative Radiation Therapy (ISIORT) was undertaken in 
order to identify the range of intraoperative radiotherapy 
(IORT) indications and techniques for various tumour sites. In 
this survey we analysed breast treatments. 
Materials and Methods: Since 2007, we collected 
demographic, clinical and technical data related to IORT 
procedures in a common database. Prospective and 
retrospective data entry was possible. The current study 
analysed 6,816 breast tumours.  
Results: Breast tumours represent 80.3% of all data of the 
ISIORT survey that encompassed 8,493 IORT procedures 
performed from 1992 to 2014. Median age of breast patients 
was 61.1 years (range 16-90). Gender was female in 99.7% 
and male in 0.3% of cases.  
In 6,702 cases (98.3%), IORT was a component of radical 
treatment for primary, newly diagnosed disease and in 114 
cases (1.7%), it was an attempt to rescue localized recurrent 
breast cancer.  
IORT was performed as a boost before or after EBRT in 3,258 
cases (47.8%) with doses of 8–12 Gy. In 3,558 cases (52.6%), 
IORT was used as single radiation treatment modality with 
doses of 18 Gy, 20 Gy or 21 Gy. The patients enrolled in study 
protocols represented 33% of those treated by a single dose 
and 6.3% of those treated by a boost dose.  
IORT was delivered after and before tumour removal in 39% 
and 61% of cases, respectively.  
In 6,406 cases (94%), IORT was performed using electrons of 
4-12 MeV energy. The most used applicators (77% of cases) 
were 5 or 6 cm in diameter and bevel angle was 0° in the 
majority of cases (88%). Four hundred and ten cases (6% of 
patients) were treated with a 50-kV x-ray source in a single 
centre. X-rays treatments were delivered by a spherical 
applicator inserted into the surgical cavity after tumour 
removal.  
Conclusions: At present, the ISIORT database represents the 
largest clinical and technical IORT data collection. 
Breast cancer is the most frequent IORT treatment performed 
in the 34 participating centres. From this analysis, it emerged 
that in most cases IORT was used as single shoot of 18-21 Gy, 
the most employed treatment modality was electron beam 
and the procedure was most frequently performed after 
tumour removal. Only a minority of patients was included in 
clinical trials. 
Further data analyses could enhance multi-institutional 
performance and serve as a basis for designing clinical trials 
in an effort to define the role of IORT in tailored 
multimodality therapeutic approaches. 
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Purpose/Objective: To assess the role of an intraoperative 
electron boost (IOERT) in combination with hypofractionated 
whole breast irradiation (WBI) in terms of in-breast tumor 
control and cosmetic outcome. 
Materials and Methods: Starting in Jan 2011, a prospective 
multi-center single arm trial is conducted by the ISIORT. 
Patients receive an IOERT boost of 10 Gy (Dmax 11.1 Gy) 
followed by a WBI of 40.5 Gy in 15 fractions (2.7 Gy single 
dose). 5-year in-breast-recurrence rates will be analyzed in 3 
different age groups (35-40 y, 41-50 y, > 50y) and tested 
against the respective best published results from 
randomized prospective trials by the use of a sequential 
probability ratio test (SPRT). Acute reactions are assessed by 
CTC-scoring, late reactions according to LENT-SOMA criteria. 
Cosmesis is evaluated by a 5-point-Scoring System (van 
Limbergen, double evaluation) starting prior to WBI on the 
basis of repeated photodocumentation in standardized 
positions. 
Results: As of August 2014, within ten active institutions 645 
patients have been recruited, 481 of them already in follow-
up. Patient and tumor characteristics are summarized in 
Table 1. For IOERT, the median energy chosen was 7 MeV 
(range 4-12) with median tube diameters of 6 cm (4-8) and 
mean prescription depths of 19 mm (6.2 SD), resulting in 
mean D90 volumes of 19 ml. Perioperatively, no major 
complications were observed. Four weeks after the end of 
WBI and 479 evaluated patients, 177 (37%) showed no 
reactions (CTC 0), 277 (58%) presented with faint (CTC 1) and 
24 (5%) with moderate to brisk erythema (CTC 2), 
respectively. Go-I late reactions (LENT-SOMA) occured in a 
mean frequency of 97%, 96%, 98% and 96% after 4-5 
months,1,2 and 3 years follow-up, respectively. Cosmesis was 
assessed postoperatively by patients themselves (subjective) 
and doctors (objective). Baseline appearance was first 
assessed after wound healing prior to WBI and scored as 
sufficient (excellent and good) in 69%/74% of 614 
subjective/447 objective evaluations. Respective results at 4-
5 months, one, two and three years post RT were 87%/75% of 
418/378, 89%/77% of 306/164, 83%/75% of 132/107 and 
84%/87.5% of 31/24 ratings. At a median follow-up period of 
12.6 months (range 0.5-37), three patients were 
metastasized, two died, no in-breast recurrence was noted. 
Tab.1 Patient characteristics  
 
Patient age (y) n  Histology  n  
35-40 15  IDC  416 
41-50 120  ILC  50  
> 50 405  mixed  46  
T-stage 
 
mucinous 8  
0 3 tubular  15  
1  460  medullary  2  
2 76  others  3 
x 1  EIC-status  
 
N-Stage 
 
negative 482 
0 467 positive 58 
1 71 Grade 
 
x 2 G1 146 
Resection status 
 
G2 305 
R0 540 G3 89 
Resection 
margins mm 
median 5(0.5-30) 
Her 2-neu 
Status  
Multifocality 
 
neg 483 
no 462 pos 57 
yes 78 HR-Status 
 
  
neg 43 
  
pos 497 
 
Conclusions: Tolerance of combined IOERT/hypofractionated 
WBI regimen is excellent, acute reactions moderate and late 
reactions insignificant in short-term assessment. With regard 
to postoperative appearance, early cosmetic results are not 
impaired. Both tumor control and cosmetic outcome have to 
be evaluated on long-term follow-up.  
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Purpose/Objective: The hypothesis is that partial breast 
irradiation after lumpectomy will have less impact on QoL, 
when compared to whole breast irradiation. We don’t know 
the impact of the different partial breast irradiation 
techniques. We therefore compared the QoL parameters 'pain 
and fatigue' for external beam APBI and IORT in our phase 2 
(feasibility) study. 
Materials and Methods: Eligible patients were women aged 
60 years or older with unilateral breast cancer with tumor 
stage Tis, T1 or T2 less than 3 cm treated within the context 
of a phase II study. For practical reasons using external beam 
APBI in one hospital, 10 daily fractions of 3.85 Gy, and IORT 
in the other hospital, 23.3 Gy in one fraction with electrons 
